Is Selenium Immune Function Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Selenium Immune Function Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - reported that 6 months of Sel improved GO-specific QoL, reduced ocular involvement, and slowed progression in patients with mild GO, supporting its incorporation into European guidance for mild, active GO, particularly in Sel-deficient areas []. [Kostadinov Nikolay (2026); evidence level 1] - Subsequent studies expanded the evidence base but introduced uncertainty: a Mexican randomized study suggested improved clinical activity and reduced progression in mild GO, whereas trials in Sel-sufficient settings and in inactive moderate-to-severe GO have reported more heterogeneous effects [,,]. [Kostadinov Nikolay (2026); evidence level 1] - Current recommendations are largely influenced by limited trial evidence, and prior syntheses have not fully clarified whether benefits differ by baseline Sel status, GO activity/severity, treatment duration, or outcome domain. [Kostadinov Nikolay (2026); evidence level 1] - 1 2 Graves’ orbitopathy (GO) is an immune-mediated inflammatory disorder of the orbit and periorbital tissues and represents the most common extrathyroidal manifestation of Graves’ disease. [Kostadinov Nikolay (2026); evidence level 1] - Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements. [Berisha-Muharremi V (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.